Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04888936|
Recruitment Status : Recruiting
First Posted : May 17, 2021
Last Update Posted : May 27, 2022
RASopathies are a group of conditions caused by a genetic change. People with a RASopathy may have developmental issues, cognitive disability, poor growth, and birth defects. They may also have an increased risk for developing cancer. Researchers want to learn more.
Objective: To learn more about RASopathies, how genes and environmental factors contribute to cancer development in people with RASopathies, and the best way to find these cancers and other conditions early or prevent them.
People of any age who have or may have a RASopathy, and their family members.
Participants will complete questionnaires about their personal and family medical history. Their medical records will be reviewed.
Participants will give blood and urine samples. They will give a saliva or cheek cell sample. Some samples will be used for genetic testing.
Participants may have a skin biopsy.
Participants may have a physical exam by the RASopathies study team. They may also have exams by additional specialists, such as dentists; urologists; ear, nose, and throat doctors; and neurologists.
Participants may have computed tomography of the face and mouth. They may have an ultrasound of the abdomen. They may have a bone density scan. They may have skeletal and/or spine x-rays. They may have magnetic resonance imaging of the brain, low back, chest, and/or heart. They may be photographed.
Participants may have other tests, such as sleep, brain and heart electrical activity, speech and swallow, metabolism, hearing, eye, and colon function tests.
Participants may sign separate consent forms for some tests.
Participation will last indefinitely. Participants may be contacted once in a while by phone or mail. They may have follow-up visits.
|Condition or disease|
|Costello Syndrome Noonan Syndrome Cardiofaciocutaneous Syndrome Legius Syndrome Capillary Arteriovenous Malformation Syndrome|
The RASopathies are a clinically defined group of disorders caused by pathogenic germline variants in genes encoding components of the Ras/mitogen-activated-protein kinase (Ras/MAPK) pathway. These disorders have overlapping clinical features due to Ras/MAPK dysfunction, including a predisposition to the development of certain malignancies. The aims of this prospective longitudinal cohort study are to determine the incidence of malignancy in patients with RASopathies and determine the underlying differences in those who develop tumors as compared to those who do not, in order to inform cancer screening recommendations. In addition, this longitudinal cohort study will provide a better understanding of non-tumor RASopathy manifestations.
To establish a longitudinal cohort of participants with a clinical diagnosis of a RASopathy and/or a pathogenic germline variation in a Ras/MAPK pathway gene (excluding NF1).
To study the lifetime rates of cancer development in participants with a RASopathy.
To longitudinally characterize germline RASopathy-related tumor and non-tumor clinical manifestations.
To create a biospecimen repository of carefully annotated tissue samples for use in subsequent etiologically oriented translational research projects.
To describe novel phenotypes associated with germline Ras/MAPK pathway genetic variation.
Number of participants meeting enrollment criteria for inclusion in the RASopathy cohort.
Development of RASopathy-associated neoplasms in patients with RASopathies other than neurofibromatosis type 1 (NF1).
Longitudinal standardized quantitative evaluations of specific RASopathy manifestations.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies|
|Actual Study Start Date :||April 25, 2022|
|Estimated Primary Completion Date :||January 31, 2025|
|Estimated Study Completion Date :||January 31, 2025|
NCI RASopathies Clinical Center Cohort
includes Proband, Other carriers in family, Family Controls
NCI RASopathies Field Cohort
includes Proband, Other carriers in family, Family Controls
- RASopathy Syndromes [ Time Frame: ongoing ]To establish a longitudinal cohort of participants with a clinical diagnosis of a RASopathy and/or a pathogenic germline variation in a Ras/MAPK pathway gene (excluding NF1).
- Clinical Phenotype [ Time Frame: ongoing ]To study the lifetime rates of cancer development in participants with a RASopathy and their unaffected family members.
- Genetic and Environmental Interactions [ Time Frame: ongoing ]To longitudinally characterize germline RASopathy-related tumor and non-tumor clinical manifestations.
- Biospecimen Repository [ Time Frame: ongoing ]To create a biospecimen repository of carefully annotated tissue samples for use in subsequent etiologically oriented translational research projects.
- Novel Phenotype [ Time Frame: ongoing ]To describe novel phenotypes associated with germline Ras/MAPK pathway genetic variation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04888936
|Contact: Stephanie M Steinbart, R.N.||(800) email@example.com|
|Contact: Douglas R Stewart, M.D.||(240) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|National Cancer Institute - Shady Grove||Recruiting|
|Rockville, Maryland, United States, 20850|
|Principal Investigator:||Douglas R Stewart, M.D.||National Cancer Institute (NCI)|